Recombinant Plasmid Compositions for Endogenous MANF Production
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Aging leads to decreased levels of neurotrophic factors, resulting in reduced tissue repair after injury, necessitating therapies that induce endogenous production of these factors.
Innovation Solution
Compositions comprising recombinant plasmids with nucleotide sequences encoding mRNA for proteins like mesencephalic astrocyte-derived neurotrophic factor (MANF) are administered to increase mRNA production and translation, using vectors like AAV6.2FF for delivery.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Quantity of substance
If aging occurs, then neurotrophic factor levels decrease, but tissue repair capability is reduced
Solution Approach 1:
The patent applies preliminary action by administering recombinant plasmids containing neurotrophic factor genes before tissue injury occurs or at the time of injury. The plasmids are introduced into cells to establish endogenous production capacity in advance, so that when tissue injury occurs, the cells can immediately produce neurotrophic factors to enhance repair capabilities. This proactive approach prevents the age-related decline in tissue repair rather than merely responding to it.
Solution Approach 2:
The patent implements self-service by enabling cells to produce their own neurotrophic factors through endogenous gene expression. The recombinant plasmids integrate into the cell's genetic machinery, allowing the cells to autonomously synthesize neurotrophic factors (such as MANF, GDNF, or BDNF) without continuous external administration. This self-producing mechanism ensures sustained neurotrophic factor levels that improve tissue repair capability independently of aging.
2Productivity
If recombinant plasmids are administered, then endogenous production of neurotrophic factors increases, but device complexity increases
Solution Approach 1:
The patent applies universality by designing a multi-functional recombinant plasmid composition that simultaneously achieves multiple objectives: (1) serves as a genetic vector to deliver neurotrophic factor genes, (2) functions as a regulatory element to control gene expression, and (3) acts as a therapeutic agent to enhance tissue repair. The plasmid backbone includes universal elements such as origin of replication, selectable markers, and multiple cloning sites that can accommodate different neurotrophic factor genes, making the composition broadly applicable to various tissue repair scenarios without requiring separate complex delivery systems for each factor.
Data Source
AI summary
Some embodiments of the present disclosure relate to one or more compositions that upregulate the production of one or more sequences of mRNA. The sequences of mRNA may encode for translation of a target biomolecule, thereby causing an increase in the bioavailability of the target biomolecule within a subject that is administered the one or more compositions. In some embodiments of the present disclosure, the target biomolecule is a protein such as MANF.